Formulation and Evaluation of Dithranol Ethosomes for Psoriasis

Psoriasis is a chronic autoimmune condition that results in the rapid growth of skin cells, causing red, scaly patches. Despite the availability of several treatments, including topical corticosteroids and biologics, managing psoriasis remains challenging due to side effects, non-compliance, and limited long-term efficacy. Dithranol, a widely used treatment for psoriasis, has proven effective due to its anti-inflammatory and antiproliferative properties. However, its clinical use is hindered by poor solubility, skin irritation, and staining of both the skin and clothing. This study aimed to develop a novel Dithranol-loaded ethosomal gel, which could enhance its solubility, stability, skin penetration, and therapeutic efficacy while minimizing irritation and side effects. Ethosomes are lipid-based nanocarriers made from phospholipids, cholesterol, and alcohol, which can improve the skin penetration of drugs and provide controlled, sustained release. Given these characteristics, ethosomes were chosen as the drug delivery system for this study to optimize the delivery of Dithranol and make it more effective for treating psoriasis. The study focused on developing a formulation that could not only improve drug absorption through the skin but also offer longer-lasting therapeutic effects. Compared to traditional Dithranol creams, the ethosomal gel showed superior therapeutic effects with fewer side effects, particularly skin irritation and burning sensations.